Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $29.39M by Medicaid between Jan 2018 and Dec 2024, across 222 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
MANTECA, CA 95337
MANTECA, CA 95337
33aNPI1740354851assigned 11/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.39M
24GClaims862,331
24DCodes billed222
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#91 of 410
Median peer was paid$6.90M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 63,335 | $906K | |
| 2019 | 89,681 | $1.07M | |
| 2020 | 89,057 | $3.44M | |
| 2021 | 118,007 | $3.82M | |
| 2022 | 145,315 | $5.05M | |
| 2023 | 158,119 | $5.72M | |
| 2024incomplete | 198,817 | $9.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 7,909 | 7,335 | $4.28M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 15,659 | 14,994 | $4.15M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 8,848 | 8,483 | $4.02M |
| 0450 | Emergency room services | 7.6% | 57,073 | 51,064 | $2.24M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.5% | 6,418 | 6,243 | $1.92M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 2,042 | 1,902 | $1.45M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.5% | 9,033 | 8,663 | $1.04M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.0% | 11,443 | 11,082 | $886K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 5,740 | 5,592 | $660K |
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 11,068 | 10,765 | $584K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 2,432 | 2,389 | $393K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,092 | 3,036 | $272K |
210 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 6,519 | $266K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,294 | $244K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,206 | $235K |
| 76830 | Ultrasound, transvaginal | <1% | 2,224 | $226K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,179 | $212K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 43,985 | $197K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,872 | $187K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,388 | $182K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,468 | $178K |
| 73630 | <1% | 2,602 | $157K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 635 | $157K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,841 | $138K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,345 | $128K |
| 73610 | <1% | 2,171 | $122K | |
| 83880 | <1% | 5,970 | $121K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,251 | $119K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,480 | $119K |
| 86900 | <1% | 2,837 | $117K | |
| 80051 | <1% | 30,049 | $114K | |
| 73130 | <1% | 1,858 | $111K | |
| 0270 | <1% | 5,421 | $108K | |
| 73560 | <1% | 2,060 | $100K | |
| 73110 | <1% | 1,535 | $100K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 674 | $98K |
| 73030 | <1% | 1,649 | $96K | |
| 82565 | <1% | 34,782 | $94K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 326 | $93K |
| 59025 | Fetal non-stress test | <1% | 675 | $93K |
| 87631 | <1% | 1,896 | $89K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,282 | $85K |
| 84702 | <1% | 6,321 | $82K | |
| G0378 | Hospital observation service, per hour | <1% | 562 | $81K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,454 | $81K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 849 | $76K |
| 82247 | <1% | 24,654 | $74K | |
| 74018 | <1% | 1,090 | $72K | |
| 84460 | <1% | 23,112 | $69K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,478 | $69K |
| 93976 | <1% | 302 | $69K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,426 | $68K |
| 81001 | <1% | 26,516 | $68K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,453 | $66K |
| 93971 | <1% | 686 | $65K | |
| 83690 | <1% | 18,029 | $65K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,628 | $60K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,629 | $60K |
| 84450 | <1% | 21,156 | $59K | |
| 82947 | <1% | 29,926 | $57K | |
| 84520 | <1% | 30,056 | $55K | |
| 0031A | <1% | 1,346 | $54K | |
| 84484 | <1% | 10,439 | $53K | |
| 73080 | <1% | 766 | $52K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 51 | $48K |
| 84075 | <1% | 19,037 | $47K | |
| 70491 | <1% | 171 | $46K | |
| 86850 | <1% | 2,187 | $46K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,749 | $46K |
| 73090 | <1% | 632 | $46K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 145 | $44K |
| 0250 | <1% | 20,487 | $43K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,022 | $43K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,858 | $42K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 607 | $41K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,232 | $41K |
| 72100 | <1% | 514 | $40K | |
| 84703 | <1% | 10,791 | $38K | |
| 86901 | <1% | 2,837 | $38K | |
| 76642 | <1% | 356 | $37K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 63 | $33K |
| 83735 | <1% | 9,393 | $32K | |
| 87040 | <1% | 3,739 | $31K | |
| 70486 | <1% | 159 | $29K | |
| 73590 | <1% | 454 | $29K | |
| 73502 | <1% | 394 | $28K | |
| 81003 | <1% | 17,808 | $28K | |
| 80306 | <1% | 2,701 | $27K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,895 | $27K |
| 73140 | <1% | 435 | $27K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,696 | $26K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 250 | $25K |
| 70496 | <1% | 92 | $25K | |
| 87088 | <1% | 6,506 | $25K | |
| 73564 | <1% | 244 | $24K | |
| 0011A | <1% | 590 | $24K | |
| 85652 | <1% | 8,101 | $22K | |
| 83605 | <1% | 3,495 | $21K | |
| 0012A | <1% | 512 | $20K | |
| 82570 | <1% | 3,109 | $20K | |
| J3490 | Unclassified drugs | <1% | 3,411 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 802 | $19K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,579 | $19K |
| 93970 | <1% | 137 | $18K | |
| 70498 | <1% | 67 | $16K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,328 | $16K |
| 85610 | <1% | 7,223 | $16K | |
| 0710 | <1% | 1,755 | $15K | |
| 82077 | <1% | 1,840 | $13K | |
| 99199 | Unlisted special service, procedure or report | <1% | 253 | $13K |
| 84100 | <1% | 5,171 | $13K | |
| 77080 | <1% | 231 | $13K | |
| 82248 | <1% | 2,497 | $12K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,413 | $12K |
| 84156 | <1% | 3,144 | $12K | |
| 76770 | <1% | 101 | $12K | |
| 76870 | <1% | 97 | $11K | |
| 71250 | <1% | 75 | $11K | |
| 72040 | <1% | 138 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 202 | $10K |
| 85379 | <1% | 2,301 | $10K | |
| 0637 | <1% | 39,237 | $10K | |
| 85027 | <1% | 2,270 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 26 | $9K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,808 | $9K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 186 | $9K |
| 86140 | <1% | 2,928 | $8K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 25 | $8K |
| 80179 | <1% | 1,113 | $8K | |
| 82310 | <1% | 1,509 | $8K | |
| 84132 | <1% | 1,710 | $8K | |
| 87449 | <1% | 590 | $7K | |
| 87210 | <1% | 1,681 | $7K | |
| 87324 | <1% | 544 | $7K | |
| 85378 | <1% | 1,324 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 927 | $6K |
| 73552 | <1% | 93 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,061 | $6K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,136 | $5K |
| 82962 | <1% | 3,445 | $5K | |
| 76857 | <1% | 54 | $5K | |
| Z7502 | <1% | 497 | $5K | |
| 82272 | <1% | 1,118 | $4K | |
| 72131 | <1% | 42 | $4K | |
| 77065 | Tomosynthesis, mammo | <1% | 37 | $4K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 82 | $4K |
| 96376 | <1% | 417 | $4K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 248 | $4K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 228 | $4K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 51 | $4K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,699 | $4K |
| 99070 | <1% | 284 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,150 | $3K |
| 12001 | <1% | 133 | $3K | |
| 73060 | <1% | 43 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 278 | $3K |
| 90715 | <1% | 95 | $2K | |
| 82803 | <1% | 368 | $2K | |
| 74022 | <1% | 42 | $2K | |
| 97165 | <1% | 25 | $2K | |
| 82550 | <1% | 646 | $2K | |
| 84295 | <1% | 491 | $2K | |
| 83615 | <1% | 383 | $2K | |
| 82040 | <1% | 520 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 389 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,050 | $2K |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $2K |
| 76882 | <1% | 23 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 25 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 140 | $2K |
| J1815 | Injection, insulin, per 5 units | <1% | 502 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 465 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 898 | $1K |
| 72170 | <1% | 16 | $1K | |
| 84550 | <1% | 378 | $1K | |
| 0636 | <1% | 77 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 20 | $1K |
| 85007 | <1% | 767 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 85 | $1K |
| 71101 | <1% | 13 | $907.03 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $740.94 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 16 | $718.92 |
| 86780 | <1% | 83 | $700.74 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 229 | $677.54 |
| 90686 | <1% | 50 | $635.33 | |
| 0272 | <1% | 26 | $584.00 | |
| 29125 | <1% | 82 | $501.56 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 26 | $488.22 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 108 | $482.65 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,095 | $478.08 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 203 | $461.16 |
| 0370 | <1% | 1,475 | $365.54 | |
| 90656 | <1% | 47 | $242.30 | |
| 88304 | <1% | 69 | $234.57 | |
| 86665 | <1% | 12 | $232.44 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 17 | $223.86 |
| 85730 | <1% | 42 | $219.11 | |
| 10060 | <1% | 13 | $165.00 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 38 | $154.58 |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 133 | $136.81 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 38 | $129.44 |
| 80178 | <1% | 24 | $110.00 | |
| 86664 | <1% | 12 | $100.42 | |
| 12011 | <1% | 14 | $90.00 | |
| 87070 | <1% | 13 | $75.10 | |
| 84155 | <1% | 40 | $71.87 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 19 | $66.87 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 71 | $53.16 |
| 96367 | <1% | 13 | $39.37 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 16 | $38.60 |
| 83930 | <1% | 13 | $36.51 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $30.57 |
| 76000 | <1% | 12 | $23.21 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 77 | $21.85 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 16 | $14.71 |
| 0258 | 0% | 300 | $0.00 | |
| 80349 | 0% | 14 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 38 | $0.00 |
| Z7610 | 0% | 42 | $0.00 | |
| 80320 | 0% | 12 | $0.00 | |
| 76376 | 0% | 150 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRIBERG, DEBORAH (SR. VP/AREA MANAGER)